The company has established partnerships with a number of partners, over and above its own organisation, in order to enable us to bring arfolitixorin to market.
Merck & Cie – experts in substance refining
Strategic research and development partnership and close collaboration. Merck & Cie is a subsidiary of Merck KGaA, Darmstadt, Germany. The partnership offers many synergies, as Isofol has specialist knowledge in the use of arfolitixorin for the treatment of cancer, while Merck has expertise in synthesising a stable MTHF API (active pharmaceutical ingredient) and in formulating a stable and sustainable drug (arfolitixorin). A global licensing agreement with Merck KGaA in Germany gives Isofol exclusive rights to develop and commercialise arfolitixorin in the field of oncology. The licensing agreement with Merck also gives Isofol access to the unique, patented MTHF/
Surgical Oncology Laboratory; SOL, (tidigare kirurg-onkologiska laboratoriet) på Östra sjukhuset i Göteborg, bedriver forskning inom kirurgi och onkologi. SOL har internationellt erkänd kunskap rörande forskning om folater, särskilt vad gäller folater och kolorektalcancer.
Recipharm is the commercial manufacturer of arfolitixorin and has validated the commercial, full-scale production method in cooperation with Isofol and Merck.
CRO – Contract Research Organisation
Contract Research Organisation; ett företag som hjälper till med det praktiska genomförandet av kliniska studier, någonting som är alldeles nödvändigt för ett företag av Isofols storlek.
CRO kan t.ex. hjälpa till med statistiska beräkningar och analyser, de kan ha databaser för studiedata, arbeta med prekliniska studier, märka och distribuera studieläkemedel samt vara företagets förlängda arm där resurser och geografiskt avstånd gör det svårt att arbeta direkt mot sjukhusen. Isofol samarbetar bland annat med både internationella och lokala CROs såsom Envigo, TFS, IDDI, PCG, Precision Oncology, PK-Expert m.fl.
Sahlgrenska University Hospital
Sahlgrenska University Hospital (SU) serves as an important clinical development platform forto Isofol Medical. SU, located in Gothenburg, hosts key clinical and medical competence as well as having modern sites for performing Isofol Medical’s clinical trials.
About Sahlgrenska University Hospital SU provides emergency and basic care for the Gothenburg region. SU also provides highly specialized care for the 1.7 million inhabitants in Western Sweden. SU was founded in 1997 when three hospitals merged; Mölndal Hospital, Sahlgrenska Hospital and Östra Hospital.
The research performed at the research institutions around SU, such as the Sahlgrenska Academy, has resulted in numerous achievements and innovations. Examples include development of the antibiotic PAS against tuberculosis and the blood thinning pharmaceutical Apekumarol. Both of these were developed after the Second World War as a result of research by Jörgen Lehmann. During the 70’s and 80’s, Arvid Carlsson and Björn Folkow successfully contributed to the development of the β-blocker Selokén and L-Dopa for Parkinson’s disease. Arvid Carlsson later won the Nobel Prize in Physiology or Medicine in 2000 for his work on the neurotransmitter Dopamine and his research lead to blockbuster pharmaceuticals. Furthermore, pharmaceuticals such as Losec and Nexium, from Astra Zeneca, have been made possible thanks to key contributions from Lars Olbe at the Sahlgrenska Academy.
Prof Bengt Gustavsson has been active at SU ever since he started his research on the effect of folates on cytotoxics in the late 1970s. The team around him at SU is closely knit, it includes medical scientists, nurses, and laboratory staff that have been involved in his clinical studies and research on the effects of folates on cytotoxics for decades.